The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 6, 2001, Pages 467-472

  Van De Poll, Matthijs E C ^a,b   Relling, Mary V ^a,b   Schuetz, Erin G ^a,b   Harrison, Patricia L ^a   Hughes, Walter ^a   Flynn, Patricia M ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Atovaquone; Cotrimoxazole; CYP3A4; Etoposide; P glycoprotein

Indexed keywords

75 H 0402; ATOVAQUONE; CATECHOL; COTRIMOXAZOLE; CYTOCHROME P450 3A4; ETOPOSIDE; GLYCOPROTEIN P; GR 151218X; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG DISPOSITION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG PROTEIN BINDING; FEMALE; HUMAN; LIVER MICROSOME; MALE; NEUTROPENIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL;

ADOLESCENT; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; ATOVAQUONE; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; NAPHTHOQUINONES; PILOT PROJECTS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0035019446     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000250     Document Type: Article

References (32)

1. 1. Blanco JG, Harrison PL, Evans WE, Relling MV (2000) Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 28:379
2. 2. Cai X, Woo MH, Edick MJ, Relling MV (1999) Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 728:241
3. 3. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA, Scott J, Marina R, Caldwell P (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180:369
4. 4. Cribb AE, Spielberg SP, Griffin GP (1995) N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23:406
5. 5. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetics systems. Comput Programs Biomed 9:115
6. 6. Deuchars KL, Ling V (1989) P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16:156
7. 7. Dubin M, Villamil SHF, Stoppani AOM (1990) Inhibition of microsomal lipid peroxidation and cytochrome P450 catalyzed reactions by B-lapachone and related naphthoquinones. Biochem Pharmacol 39:1151
8. 8. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HHJ, Eng R, Hooton TM, Kerkering TM, Schutz M, van der Horst C, Hafner R (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 339:1889
9. 9. Fleming RA, Evans WE, Arbuck SG, Stewart CF (1992) Factors affecting in vitro protein binding of etoposide in humans. J Pharm Sci 81:259
10. 10. Gantchev TG, Hunting DJ (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 53:422
11. 11. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316:1627
12. 12. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C (1993) Comparison of atovaquone (566C80) with trimethoprimsulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328:1521
13. 13. Jensen PB, Roed H, Skovsgaard T, Friche E, Vindelov L, Hansen HH, Spang-Thomsen M (1990) Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother Pharmacol 27:194
14. 14. Kool M, van der LM, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914
15. 15. Lan LB, Ayesh S, Lyubimov E, Pashinsky I, Stein WD (1996) Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol 38:181
16. 16. Lowis SP, Pearson ADJ, Newell DR, Cole M (1993) Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 53:4881
17. 17. Ngo LY, Yogev R, Dankner WM, Hughes WT, Burchett S, Xu K, Sadler B, Unadkat JD (1999) Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Antimicrob Agents Chemother 43:1516
18. 18. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L, Osterlind K (1993) Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7:1975
19. 19. Pui C-H, Ribeiro R, Hancock ML, Rivera GK, Evans WE, Raimondi S, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist W (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med 325:1682
20. 20. Raderer M, Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72:3553
21. 21. Relling MV (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18:350
22. 22. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR (1994) O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352
23. 23. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH (1998) Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12:346
24. 24. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698
25. 25. Smit JW, Schinkel AH, Muller M, Weert B, Meijer DK (1998) Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27:1056
26. 26. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031
27. 27. Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J, Ohira M, Nishimura K (1993) High frequency of etoposide-related secondary leukemia in children with non-hodgkin's lymphoma. Am J Pediatr Hematol Oncol 15:99
28. 28. Tiberghien F, Loor F (1996) Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 7:568
29. 29. van Asperen J, Tellingen OV, Beijnen JH (2000) The role of MDR1A-p-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28:264
30. 30. van Maanen JMS, DeVries J, Pappie D, et al (1987) Cytochrome P450-mediated O-demethylation: a route in the metabolic activation of etoposide. Cancer Res 47:4658
31. 31. Weaver RJ, Dickins M, Burke MD (1993) Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. Biochem Pharmacol 46:1183
32. 32. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR (1993) Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209